1389. Leishmaniasis
Session: Symposium: Update on New IDSA Guidelines: Streptococcal Pharyngitis, Leishmaniasis, and Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery
Sunday, October 23, 2011: 8:00 AM
Room: 104ABC
An status update on the development of IDSA clinical practice guidelines for the numerous and diverse clinical syndromes caused by the protozoan parasites of the Leishmania complex will be presented highlighting our approach to difficult management problems facing both developed and developing world clinicians.

Alan J. Magill, MD, FACP, FIDSA, Division of Experimental Therapeutics, WRAIR, Walter Reed Army Institute of Research, Kensington, MD

Dr. Alan Magill MD, FACP, FIDSA is a Program Manager at the Defense Advanced Research Projects Agency (DARPA) where he initiates innovative and disruptive technology research and development programs. His current portfolio includes a $100M effort influenza vaccine program. He recently retired from 27 years active duty service in the US Army. He was formerly at the Walter Reed Army Institute of Research (WRAIR) in Washington DC, USA, where he spent the last 20 years developing new generations of vaccines, diagnostics, and drugs directed against malaria and leishmaniasis. He is an Associate Professor at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, the current (2011-2013) immediate Past President of the International Society of Travel Medicine (ISTM), the Lead Editor of the 9th edition of Hunterís Tropical Medicine and a Medical Editor of the CDC Health Information for International Travel (the yellow book) for 2010 and 2012.

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.